Premium
Patients with atopic dermatitis with filaggrin loss‐of‐function mutations show good but lower responses to immunosuppressive treatment
Author(s) -
Roekevisch E.,
Leeflang M.M.G.,
Schram M.E.,
Campbell L.E.,
Irwin McLean W.H.,
Kezic S.,
Bos J.D.,
Spuls P.I.,
MiddelkampHup M.A.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15191
Subject(s) - atopic dermatitis , filaggrin , medicine , randomization , methotrexate , azathioprine , randomized controlled trial , dermatology , mutation , immunology , biology , gene , disease , genetics
Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.(1) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved.